KRAS and cancer: Following the initial hit mutation in the Apc gene that leads to Wnt signaling overactivation, mutations deregulating other pathways (such as KRAS/TGFb and p53) sequentially accumulate in cancer cells, and correlate with cancer progression [37, 38].